Global Liquid Biopsy Market: By Products and Services (Instruments, Reagents, and Services & Software), By Biomarker Type (Circulating Tumor Cells (CTC), Circulating Tumor DNA (ctDNA), Exosomes, and Others), By Sample Type (Blood Samples, Urine Samples, and Other Biofluid Samples), By Application (Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Leukemia, Lung Cancer, Prostate Cancer, and Other Cancers), By Analysis Method (Multi - gene - parallel Analysis and Single Gene Analysis (PCR Microarrays)), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

September 2017 | 197 pages | ID: G7496837A72EN
Precision Business Insights (PBI)

Abstracts

Global Liquid Biopsy Market Report Description:

Global liquid biopsy market report gives comprehensive outlook on liquid biopsy products and services across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on liquid biopsy market gives historical, current, and future market sizes (US$ Mn) on the basis of product & services type, biomarker type, sample type, application, analysis method, end user, and geographic regions. This report studies liquid biopsy market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, liquid biopsy market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed liquid biopsy market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the liquid biopsy market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in manufacturing, supply and usage of liquid biopsy products and services.

Global Liquid Biopsy Market:

Global liquid biopsy market estimated to be valued US$ 734 Mn in 2017 and poised to grow at CAGR of 21.4% over 2017-2023. Market for liquid biopsy projected to reach US$ 2345 Mn by 2023 owing to growing need for effective and non-invasive cancer diagnostic tools.

Trusted alternative to conventional cancer screening method

Global liquid biopsy market is gaining traction in recent times owing to its accurate, effective results in comparison with traditional cancer screening methods, which are achieved through minimal invasiveness and expenses. Challenges associated with traditional biopsy such as invasiveness, ill informed results, post sampling medical challenges and costs are prompting the healthcare professionals to adopt less invasive liquid biopsy tests for cancer screening and management, which is projected to create significant market demand for liquid biopsy products and services over the forecast period. Moreover, several clinical research activities related to liquid biopsy biomarkers are in late stage and it is expected that, upon successful launch and commercialization of these tests over the forecast period will result into significant market growth.

Growing investment in liquid biopsy products R&D and commercialization is projected to drive the market revenue growth

Players in the global liquid biopsy market increasingly attracting the investments in recent times for development and commercialization of late stage products through IPOs. For instance, RainDance Technologies and Biocept filled IPOs in 2015 and 2014 respectively to develop advanced liquid biopsy technologies to aid physicians to devise suitable treatment strategies. Moreover, growing awareness among key stakeholders regarding liquid biopsy assays expected to drive market demand for these tests over the forecast period across the globe.

North America emerged as prominent region for liquid biopsy market across the globe

North America market expected to hold the higher revenue share in global liquid biopsy market and projected to remain same over the forecast period owing to accessibility, availability of advanced diagnostic tools such as liquid biopsy in the region. Asia-pacific liquid biopsy market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to large medical unmet need in the region.

COMPETITION ASSESSMENT

Key players profiles in the global Liquid Biopsy market include:

• Biocept Inc. (U.S)
• Bio-Rad Laboratories Inc. (U.S)
• Fraunhofer-Gesellschaft (Germany)
• Guardant Health, Inc. (U.S)
• Janssen Diagnostics, LLC (U.S)
• MDxHealth SA (U.S)
• Myriad Genetics (U.S)
• QIAGEN (Netherlands)
• RainDance Technologies, Inc. (U.S)
• Roche (Switzerland)
• Trovagene Inc. (U.S)

Players in liquid biopsy market are focusing on development and commercialization of late stage tests through investigative and observational studies to garner larger market revenue share in global liquid biopsy market

KEY FINDINGS OF THE REPORT:

• Global liquid biopsy market expanding at 21.4% CAGR over 2017 to 2023 to reach market value of US$ 2345 Mn by 2023
• Based on biomarker type, Circulating Tumor DNA (ctDNA) expected to emerge as larger revenue generating segment end of the forecast period owing to numerous late stage pipeline clinical trials for ctDNA
• Blood samples are prominent source for liquid biopsy tests and accounted for larger market revenue share in 2016 expected to remain attractive over the forecast period
• Players are focusing on developing technologically advanced tests to detect the biomarkers

KEY FEATURES OF THE REPORT:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

DETAILED SEGMENTATION

By Products and Services

• Instruments
• Reagents
• Services and Software

By Biomarker Type

• Circulating Tumor Cells (CTC)
• Circulating Tumor DNA (ctDNA)
• Exosomes
• Others

By Sample Type

• Blood Samples
• Urine Samples
• Other Biofluid Samples

By Application

• Breast Cancer
• Colorectal Cancer
• Gastrointestinal Cancer
• Leukemia
• Lung Cancer
• Prostate Cancer
• Other Cancers

By Analysis Method

• Multi - gene - parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

By End User

• Hospitals
• Diagnostic Laboratories
• Academic and Research Institutes

By Geography

• North America
• U.S
• Canada
• Europe
• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America
• Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa

Rest of MEA

Contents

1. RESEARCH METHODOLOGY

1.1. Secondary and Primary research
  1.1.1. Secondary Sources
  1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms

2. SCOPE OF STUDY

2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study

3. EXECUTIVE SUMMARY

4. GLOBAL LIQUID BIOPSY MARKET DYNAMICS

4.1. Drivers
  4.1.1. Economic Drivers
  4.1.2. Demand Side Drivers
  4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends

5. UNIQUE FEATURES OF THE REPORT

5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis

6. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY PRODUCTS AND SERVICES, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Instruments
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Reagents
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Services and Software
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY BIOMARKER TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Circulating Tumor Cells (CTC)
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Circulating Tumor DNA (ctDNA)
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Exosomes
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Others
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY SAMPLE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Blood Samples
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Urine Samples
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Other Biofluid Samples
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Breast Cancer
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.2. Colorectal Cancer
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.3. Gastrointestinal Cancer
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.4. Leukemia
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.5. Lung Cancer
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.6. Prostate Cancer
  9.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.7. Other Cancers
  9.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

10. GLOBAL LIQUID BIOPSY MARKET ANALYSIS, BY ANALYSIS METHOD, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Multi - gene - parallel Analysis (NGS)
  10.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
10.2. Single Gene Analysis (PCR Microarrays)
  10.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

11. GLOBAL LIQUID BIOPSY MARKET FORECAST, BY END USER ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Hospitals
  11.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  11.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
11.2. Diagnostic Laboratories
  11.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  11.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
11.3. Academic and Research Institutes
  11.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  11.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

12. LIQUID BIOPSY MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. North America Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  12.1.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.1.1.1. Instruments
    12.1.1.2. Reagents
    12.1.1.3. Services and Software
  12.1.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.1.2.1. Circulating Tumor Cells (CTC)
    12.1.2.2. Circulating Tumor DNA (ctDNA)
    12.1.2.3. Exosomes
    12.1.2.4. Others
  12.1.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.1.3.1. Blood Samples
    12.1.3.2. Urine Samples
    12.1.3.3. Other Biofluid Samples
  12.1.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.1.4.1. Breast Cancer
    12.1.4.2. Colorectal Cancer
    12.1.4.3. Gastrointestinal Cancer
    12.1.4.4. Leukemia
    12.1.4.5. Lung Cancer
    12.1.4.6. Prostate Cancer
    12.1.4.7. Other Cancers
  12.1.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.1.5.1. Multi - gene - parallel Analysis (NGS)
    12.1.5.2. Single Gene Analysis (PCR Microarrays)
  12.1.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.1.6.1. Hospitals
    12.1.6.2. Diagnostic Laboratories
    12.1.6.3. Academic and Research Institutes
  12.1.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.1.7.1. U.S.
    12.1.7.2. Canada
12.2. Europe Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  12.2.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.2.1.1. Instruments
    12.2.1.2. Reagents
    12.2.1.3. Services and Software
  12.2.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.2.2.1. Circulating Tumor Cells (CTC)
    12.2.2.2. Circulating Tumor DNA (ctDNA)
    12.2.2.3. Exosomes
    12.2.2.4. Others
  12.2.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.2.3.1. Blood Samples
    12.2.3.2. Urine Samples
    12.2.3.3. Other Biofluid Samples
  12.2.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.2.4.1. Breast Cancer
    12.2.4.2. Colorectal Cancer
    12.2.4.3. Gastrointestinal Cancer
    12.2.4.4. Leukemia
    12.2.4.5. Lung Cancer
    12.2.4.6. Prostate Cancer
    12.2.4.7. Other Cancers
  12.2.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.2.5.1. Multi - gene - parallel Analysis (NGS)
    12.2.5.2. Single Gene Analysis (PCR Microarrays)
  12.2.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.2.6.1. Hospitals
    12.2.6.2. Diagnostic Laboratories
    12.2.6.3. Academic and Research Institutes
  12.2.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.2.7.1. U.K
    12.2.7.2. Germany
    12.2.7.3. France
    12.2.7.4. Italy
    12.2.7.5. Spain
    12.2.7.6. Russia
    12.2.7.7. Poland 12.2.7.8. Rest of Europe
12.3. Asia-Pacific Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  12.3.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.3.1.1. Instruments
    12.3.1.2. Reagents
    12.3.1.3. Services and Software
  12.3.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.3.2.1. Circulating Tumor Cells (CTC)
    12.3.2.2. Circulating Tumor DNA (ctDNA)
    12.3.2.3. Exosomes
    12.3.2.4. Others
  12.3.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.3.3.1. Blood Samples
    12.3.3.2. Urine Samples
    12.3.3.3. Other Biofluid Samples
  12.3.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.3.4.1. Breast Cancer
    12.3.4.2. Colorectal Cancer
    12.3.4.3. Gastrointestinal Cancer
    12.3.4.4. Leukemia
    12.3.4.5. Lung Cancer
    12.3.4.6. Prostate Cancer
    12.3.4.7. Other Cancers
  12.3.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.3.5.1. Multi - gene - parallel Analysis (NGS)
    12.3.5.2. Single Gene Analysis (PCR Microarrays)
  12.3.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.3.6.1. Hospitals
    12.3.6.2. Diagnostic Laboratories
    12.3.6.3. Academic and Research Institutes
  12.3.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.3.7.1. Japan
    12.3.7.2. China
    12.3.7.3. India
    12.3.7.4. ASEAN
    12.3.7.5. Australia & New Zealand 12.3.7.6. Rest of Asia-Pacific
12.4. Latin America Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  12.4.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.4.1.1. Instruments
    12.4.1.2. Reagents
    12.4.1.3. Services and Software
  12.4.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.4.2.1. Circulating Tumor Cells (CTC)
    12.4.2.2. Circulating Tumor DNA (ctDNA)
    12.4.2.3. Exosomes
    12.4.2.4. Others
  12.4.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.4.3.1. Blood Samples
    12.4.3.2. Urine Samples
    12.4.3.3. Other Biofluid Samples
  12.4.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.4.4.1. Breast Cancer
    12.4.4.2. Colorectal Cancer
    12.4.4.3. Gastrointestinal Cancer
    12.4.4.4. Leukemia
    12.4.4.5. Lung Cancer
    12.4.4.6. Prostate Cancer
    12.4.4.7. Other Cancers
  12.4.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.4.5.1. Multi - gene - parallel Analysis (NGS)
    12.4.5.2. Single Gene Analysis (PCR Microarrays)
  12.4.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.4.6.1. Hospitals
    12.4.6.2. Diagnostic Laboratories
    12.4.6.3. Academic and Research Institutes
  12.4.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.4.7.1. Brazil
    12.4.7.2. Mexico
    12.4.7.3. Argentina
    12.4.7.4. Venezuela
    12.4.7.5. Rest of Latin America
12.5. Middle East & Africa (MEA) Liquid Biopsy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  12.5.1. Products and Services Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.5.1.1. Instruments
    12.5.1.2. Reagents
    12.5.1.3. Services and Software
  12.5.2. Biomarker Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.5.2.1. Circulating Tumor Cells (CTC)
    12.5.2.2. Circulating Tumor DNA (ctDNA)
    12.5.2.3. Exosomes
    12.5.2.4. Others
  12.5.3. Sample Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.5.3.1. Blood Samples
    12.5.3.2. Urine Samples
    12.5.3.3. Other Biofluid Samples
  12.5.4. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.5.4.1. Breast Cancer
    12.5.4.2. Colorectal Cancer
    12.5.4.3. Gastrointestinal Cancer
    12.5.4.4. Leukemia
    12.5.4.5. Lung Cancer
    12.5.4.6. Prostate Cancer
    12.5.4.7. Other Cancers
  12.5.5. Analysis Method Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.5.5.1. Multi - gene - parallel Analysis (NGS)
    12.5.5.2. Single Gene Analysis (PCR Microarrays)
  12.5.6. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.5.6.1. Hospitals
    12.5.6.2. Diagnostic Laboratories
    12.5.6.3. Academic and Research Institutes
  12.5.7. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    12.5.7.1. Gulf Cooperation Council (GCC) Countries
    12.5.7.2. Israel
    12.5.7.3. South Africa
    12.5.7.4. Rest of MEA

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Component & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. Biocept Inc. (U.S)
  13.2.2. Bio-Rad Laboratories Inc. (U.S)
  13.2.3. Fraunhofer-Gesellschaft (Germany)
  13.2.4. Guardant Health, Inc. (U.S)
  13.2.5. Janssen Diagnostics, LLC (U.S)
  13.2.6. MDxHealth SA (U.S)
  13.2.7. Myriad Genetics (U.S)
  13.2.8. QIAGEN (Netherlands)
  13.2.9. RainDance Technologies, Inc. (U.S)
  13.2.10. Roche (Switzerland)
  13.2.11. Trovagene Inc. (U.S)